Hormone Replacement Therapy Market Size and Forecast 2033

<h2>Hormone Replacement Therapy Market Size, Share, Trends Analysis</h2>
The <strong>hormone replacement therapy market</strong> was valued at<strong> USD 24.3 billion in 2023</strong>. It is expected to reach <strong>USD 50.5 billion by 2033</strong>, with a <strong>CAGR of 7.8%</strong> during the forecast period from 2024 to 2033.

The surge in demand for new advanced technologies and the rise in hormonal disorders are some of the main key driving factors for the hormone replacement therapy market. Hormone replacement therapy is also known as HRT, used for treating women who have low hormone levels such as women undergoing menopause. Hormone replacement therapy has another name also known as estrogen replacement therapy. With HRT, a woman can take estrogen, and generally progestin to help the symptoms which is caused by low hormone levels in her body.

<img class="aligncenter wp-image-43009" src="https://marketresearch.biz/wp-content/uploads/2024/01/Hormone-Replacement-Therapy-Market-By-Disease-Type.jpg" alt="Hormone Replacement Therapy Market By Disease Type" width="744" height="455">

According to a report published by June 2023, PCOS affects a projected 8 to 13% of reproductive-aged women. More than 70% of affected women are still undiagnosed globally. Moreover, a report published by the National Library of Medicine in February 2023, highlights that the global occurrence of PCOS ranges from 6% to 21% which is associated with different diagnostic categories, ethnicities, and regions.

There are almost 1.55 million new examples of PCOS in women of reproductive age globally and 17.23% of such cases were women between the age of 21 to 30 years. It is characterized by high risks of concurrent metabolic instabilities. More than 50% of PCOS patients have obesity and 31.1% have impaired glucose regulation as well as 7.5% have type 2 diabetes.

Hormone replacement therapy is generally utilized to treat the symptoms of menopausal changes, however, it is useful for treating PCOS. HRT helps to control and regulate menstrual cycles, decreases acne and hirsutism, and enhances fertility. There are many types of HRT for treating PCOS. Some of the most common HRTs are progesterone and estrogen. In HRT, progesterone is used to control menstrual cycles and decreases the risk of endometrial cancer.

Whereas, in estrogen, HRT diminution the seriousness of signs like hot flashes and night sweats. There are several other advantages of using HRT for treating PCOS such as it regulates the menstrual flow and cycle, decreases the risk of endometrial cancer, and enhances the chance of <a href="https://marketresearch.biz/report/fertility-services-market/">fertility</a>. The demand for hormone replacement therapy will increase due to its requirement to control many women's hormonal disorders which will help in market expansion during the forecasted period.

<h2>激素替代疗法市场规模、份额及趋势分析</h2>

激素替代疗法市场在2023年达到了<em>2430亿美元</em>的价值规模。预计到2033年将达到<em>5050亿美元</em>，在2024年至2033年的预测期内，年复合增长率将达到<em>7.8%</em>。

对新型先进技术的需求激增以及内分泌失调的增多是推动激素替代疗法市场增长的主要关键因素。激素替代疗法亦称为HRT，用于治疗激素水平低下的女性，例如处于更年期的女性。激素替代疗法还被称为雌激素替代疗法。通过HRT，女性可以摄入雌激素，以及通常的孕酮，以帮助缓解因体内激素水平低下而引起的症状。

<img class="aligncenter wp-image-43009" src="https://marketresearch.biz/wp-content/uploads/2024/01/Hormone-Replacement-Therapy-Market-By-Disease-Type.jpg" alt="按疾病类型划分的激素替代疗法市场" width="744" height="455">

根据2023年6月发布的一份报告，多囊卵巢综合征（PCOS）预计影响着8%至13%的生育年龄女性。全球范围内，超过70%的受影响女性尚未得到诊断。此外，美国国立医学图书馆于2023年2月发布的一份报告强调，全球PCOS的发病率介于6%至21%，与不同的诊断类别、民族和地区相关。

全球约有155万例新的PCOS病例出现在生育年龄的女性中，其中17.23%的病例为21至30岁的女性。它以并发代谢不稳定的高风险为特征。超过50%的PCOS患者患有肥胖，31.1%的患者存在葡萄糖调节受损，以及7.5%的患者患有2型糖尿病。

激素替代疗法通常用于治疗更年期变化的症状，然而，它对于治疗PCOS也十分有效。HRT有助于控制和调节月经周期，减少痤疮和多毛症，并提高生育能力。存在多种类型的HRT用于治疗PCOS。其中一些最常见的是孕酮和雌激素。在HRT中，孕酮用于控制月经周期并降低子宫内膜癌的风险。

而雌激素HRT则减轻了诸如潮热和夜间出汗等症状的严重程度。使用HRT治疗PCOS的其他优势还包括它调节月经流量和周期，降低子宫内膜癌的风险，并提高生育机会。由于激素替代疗法对于控制许多女性的内分泌失调的需求增加，预计在预测期内其需求将增长，从而有助于市场的扩张。